grinboss

Zimmer Biomet

ZBH

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $103.32 (close on November 18) and with the other assumptions at their starting point, Zimmer Biomet's sales would need to grow 3.0% a year for ten years; over its last decade, the median was 2.8%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
12/20155,998—8.6%
12/20167,68428.1%11.4%
12/20177,8241.8%10.9%
12/20187,9331.4%1.3%
12/20197,9820.6%15.3%
12/20206,128−23.2%2.6%
12/20216,82711.4%13.7%
12/20226,9401.6%11.5%
12/20237,3946.5%18.6%
12/20247,6793.8%18.1%
12/20258,2327.2%14.4%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Zimmer Biomet files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 6.5% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 18.1% of sales.
  • Working capital needed to grow: $30.8 per $100 of new sales.
  • Capital spending: 2.7% of sales.
  • Stock pay to employees: 2.3% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Its share price moves less than the market: a five-year beta of 0.65; the median is 0.94.
  • It is growing faster than before: 6.5% a year in the last three fiscal years, against 2.8% over the whole decade.
  • Its margin has risen over these years, from 11% to 18%.
  • It sold more than the year before in 9 of the last 10 years.

Against

  • It ties up $31 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
  • It owes a lot: its net debt equals 3.2 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).
  • Its sales grew 3.2% a year on average over 10 years, from $6.0 billion to $8.2 billion; the median of grinboss companies is 6.6%.
  • Its margin jumps from one year to the next: 6.4 points on average, and up to 14.0 in a single year; the median is 2.8 points.

Next results: February 9, 2027.

Other companies in its sector (Health Care)

Zoetis (ZTS) · Agilent Technologies (A) · AbbVie (ABBV) · Abbott Laboratories (ABT) · Align Technology (ALGN) · Alnylam Pharmaceuticals (ALNY) · Amgen (AMGN) · Baxter International (BAX) · All companies

Loading the model…